• CStone’s MEK inhibitor approved for trials in China pharmaceutical-technology
    August 01, 2018
    CStone Pharmaceuticals has announced its CS3006, a small molecule inhibitor of mitogen-activated protein kinase (MEK), has received investigational new drug approval for clinical trials from the China National Drug Administration (CNDA). This comes only t
PharmaSources Customer Service